What You Need To Know
Hackensack Meridian Health is pleased to offer the new renal denervation (RDN) procedure for certain patients with high blood pressure. Recently approved by the U.S. Food and Drug Administration (FDA), the Symplicity Spyral™ renal denervation (RDN) system – involves a minimally invasive procedure that targets nerves near the kidneys that can become overactive and cause high blood pressure. The procedure – also known as the Symplicity™ blood pressure procedure – is approved for use as an adjunctive treatment in patients with high blood pressure (or hypertension) when lifestyle changes and antihypertensive medications do not adequately control blood pressure.
Hackensack University Medical Center’s Pranaychandra Vaidya, M.D., chief, Cath Lab & director of Quality Improvement at the Heart and Vascular Hospital, Hackensack University Medical Center (HUMC); along with Gregory Simonian, M.D., director of the Cardiovascular Center of Excellence and vascular surgeon, HUMC; and Haroon Faraz, M.D., director of Interventional Cardiology at HUMC; treated their first patient with the Symplicity blood pressure procedure July 30.
Jersey Shore University Medical Center is prepared to begin treating patients with Symplicity later this summer, and JFK University Medical Center within the next couple months.
Hypertension is the single largest contributor to death, and affects about 50% of U.S. adults. Of the U.S. adults who are aware of their hypertension, about 80% do not have it under control.
The Symplicity blood pressure procedure is clinically proven to help reduce high blood pressure, which can lower serious health risks. After mild sedation, the doctor inserts a very thin tube into the artery leading to the kidney. The doctor then administers energy to calm the excessive activity of the nerves connected to the kidney. The tube is removed, leaving no implant behind.